k119_108959_1	ResF|penA_1_AF515059_1	26.3	487	543	581	4.31e-31	126
k119_108959_1	NCBI|WP_063852694.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	22.3	480	543	668	1.61e-11	65.9
k119_108959_1	NCBI|WP_063852700.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	22.3	480	543	668	2.12e-11	65.5
k119_108959_1	SARG|gb|AQX82857.1|ARO:3004185|mecD	23.1	455	543	678	7.89e-10	60.5
k119_96170_7	SARG|ZP_04433866	59.1	115	120	288	1.18e-42	140
k119_96170_7	SARG|ZP_03949893	59.1	115	120	288	1.18e-42	140
k119_96170_7	SARG|ZP_03984017	59.1	115	120	288	1.18e-42	140
k119_96170_7	SARG|YP_002929946	57.6	125	120	282	1.43e-42	140
k119_96170_7	SARG|ZP_04528247	60.5	119	120	279	5.30e-42	138
k119_96170_7	SARG|ZP_03958019	54.7	128	120	317	9.16e-42	139
k119_96170_7	SARG|YP_002937728	58.9	129	120	289	1.67e-39	132
k119_96170_7	SARG|ZP_03945515	54.2	120	120	291	9.75e-39	130
k119_96170_7	SARG|ZP_03941859	52.5	120	120	288	1.57e-36	124
k119_96170_7	SARG|ZP_03938934	52.5	120	120	288	1.57e-36	124
k119_141162_2	SARG|gi|452996213|gb|AGG19398.1|	31.0	232	391	268	1.01e-28	112
k119_141162_2	SARG|gi|498515090|ref|WP_010815297.1|	31.0	232	391	268	1.01e-28	112
k119_141162_2	SARG|gi|403023847|gb|EJY36064.1|	32.4	188	391	200	2.82e-28	108
k119_141162_2	SARG|gi|452996227|gb|AGG19410.1|	32.4	188	391	252	9.66e-28	108
k119_141162_2	SARG|gi|488259314|ref|WP_002330522.1|	32.4	188	391	268	1.36e-27	108
k119_141162_2	SARG|gi|1036536100|emb|SAM71699.1|	32.4	188	391	268	1.36e-27	108
k119_141162_2	SARG|Q47746	30.5	223	391	268	1.36e-27	108
k119_141162_2	SARG|gi|403219412|emb|CCJ27774.1|	32.4	188	391	268	1.36e-27	108
k119_141162_2	SARG|KF823969.1.gene3.p01	32.4	188	391	268	1.36e-27	108
k119_141162_2	SARG|ACP19238	32.8	189	391	296	9.73e-24	99.0
k119_134834_2	SARG|AAY52004	24.7	219	315	322	3.91e-16	76.6
k119_134834_2	SARG|NP_878015	23.6	220	315	322	3.33e-15	73.9
k119_134834_2	SARG|gi|749574782|ref|WP_040203616.1|	25.8	225	315	323	1.13e-14	72.4
k119_134834_2	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	22.7	220	315	322	1.04e-12	66.6
k119_141318_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	29.6	270	292	346	1.89e-22	94.4
k119_109275_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	65	66	231	2.68e-09	49.7
k119_109275_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	65	66	231	2.68e-09	49.7
k119_109275_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.0	65	66	231	2.68e-09	49.7
k119_109275_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.5	62	66	233	2.71e-09	49.7
k119_109275_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	41.0	61	66	230	3.69e-09	49.3
k119_109275_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	65	66	231	3.71e-09	49.3
k119_109275_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	41.9	62	66	235	9.95e-09	48.1
k119_109275_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.1	64	66	232	1.36e-08	47.8
k119_109275_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.1	64	66	232	1.36e-08	47.8
k119_109275_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.1	64	66	232	1.36e-08	47.8
k119_109275_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.3	149	141	232	2.18e-24	92.8
k119_109275_3	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.6	142	141	229	2.88e-24	92.4
k119_109275_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.3	146	141	228	1.10e-23	90.9
k119_109275_3	SARG|ZP_02848503	35.9	145	141	221	1.20e-20	82.8
k119_109275_3	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	31.6	155	141	252	1.66e-14	67.0
k119_99685_3	SARG|gb|AAA26793|ARO:3003748|oleC	25.7	253	503	325	1.64e-21	94.4
k119_99685_3	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	25.7	253	503	325	2.22e-21	94.0
k119_99685_3	SARG|P42332	23.4	222	503	306	1.42e-17	82.4
k119_99685_3	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	23.4	222	503	306	1.42e-17	82.4
k119_99685_3	SARG|gi|510143239|gb|AGN36970.1|	23.4	222	503	313	1.55e-17	82.4
k119_99685_3	SARG|ABB80128	23.4	222	503	306	1.91e-17	82.0
k119_99685_3	SARG|AAD21213	23.4	222	503	306	4.68e-17	80.9
k119_99685_3	SARG|YP_001373621	21.6	231	503	318	3.41e-15	75.5
k119_99685_3	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.0	246	503	351	2.06e-12	67.4
k119_99685_3	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	23.6	246	503	351	1.16e-11	65.1
k119_112510_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.6	188	195	703	2.28e-39	141
k119_45108_3	SARG|ZP_04679156	25.0	308	343	451	1.49e-25	105
k119_45108_3	SARG|gi|686396521|ref|WP_031908504.1|	26.3	319	343	451	3.79e-25	104
k119_45108_3	SARG|gi|763462741|ref|WP_044292157.1|	26.8	325	343	451	3.79e-25	104
k119_45108_3	SARG|gi|446573715|ref|WP_000651061.1|	26.8	325	343	451	3.79e-25	104
k119_45108_3	SARG|gi|565830932|ref|WP_023914633.1|	26.3	319	343	451	5.16e-25	103
k119_45108_3	SARG|gi|686294396|ref|WP_031862836.1|	26.8	325	343	451	5.16e-25	103
k119_45108_3	SARG|Q2G140	26.8	325	343	451	5.16e-25	103
k119_45108_3	SARG|gi|727742662|ref|WP_033858866.1|	26.8	325	343	451	5.16e-25	103
k119_45108_3	SARG|gi|686329335|ref|WP_031878923.1|	26.3	319	343	451	7.05e-25	103
k119_45108_3	SARG|gi|727749287|ref|WP_033861814.1|	26.8	325	343	451	7.05e-25	103
k119_13245_5	SARG|gi|921979807|ref|WP_053271336.1|	32.3	223	246	648	1.39e-30	118
k119_13245_5	SARG|gi|507044560|ref|WP_016115614.1|	29.4	221	246	306	2.91e-27	105
k119_13245_5	SARG|gi|446026113|ref|WP_000103968.1|	29.4	221	246	306	4.06e-27	105
k119_13245_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.6	229	246	664	1.07e-24	101
k119_13245_5	SARG|gi|1045390184|ref|WP_065479071.1|	31.9	216	246	605	2.17e-23	97.4
k119_13245_5	SARG|gi|663330365|ref|WP_030329892.1|	32.1	218	246	607	4.00e-23	96.7
k119_13245_5	SARG|gi|764446018|ref|WP_044369325.1|	31.5	216	246	605	5.42e-23	96.3
k119_13245_5	SARG|gi|695865802|ref|WP_032778631.1|	31.5	216	246	605	7.36e-23	95.9
k119_13245_5	SARG|gi|662175949|ref|WP_030118884.1|	32.1	218	246	605	7.36e-23	95.9
k119_13245_5	SARG|gi|663155409|ref|WP_030194633.1|	32.1	218	246	605	7.36e-23	95.9
k119_147757_3	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.2	250	244	703	1.98e-45	160
k119_93369_5	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	41.2	68	70	574	1.30e-10	53.9
k119_93369_6	SARG|gb|WP_104671188.1|ARO:3003948|efrA	56.1	41	52	575	2.14e-10	52.4
k119_138398_2	SARG|gb|ABA71733.1|ARO:3002972|vanTG	36.5	288	338	712	1.51e-39	147
k119_138398_2	SARG|gi|498467693|ref|WP_010773049.1|	31.6	272	338	700	4.20e-28	114
k119_138398_2	SARG|gb|ABX54689.1|ARO:3002973|vanTmL	32.1	209	338	329	2.32e-26	105
k119_138398_2	SARG|AAY67970	29.4	262	338	698	3.54e-20	90.5
k119_138398_2	SARG|gi|657686198|ref|WP_029487032.1|	29.5	268	338	698	4.76e-20	90.1
k119_138398_2	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	29.4	255	338	700	4.77e-20	90.1
k119_138398_2	SARG|AF162694.1.gene4.p01	29.5	268	338	698	6.40e-20	89.7
k119_138398_2	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	29.1	251	338	700	1.56e-19	88.6
k119_138398_2	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	28.3	251	338	700	3.78e-19	87.4
k119_138398_2	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	27.6	257	338	706	3.16e-17	81.6
k119_138398_3	SARG|gb|ABA71733.1|ARO:3002972|vanTG	38.7	341	349	712	1.38e-74	243
k119_138398_3	SARG|gi|498467693|ref|WP_010773049.1|	39.3	341	349	700	2.27e-73	239
k119_138398_3	SARG|FJ872411.1.gene43.p01	38.4	341	349	702	3.42e-72	236
k119_138398_3	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	37.0	341	349	366	6.04e-71	224
k119_138398_3	SARG|JF802084.2.gene3.p01	36.5	340	349	700	6.91e-70	230
k119_138398_3	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	37.4	342	349	700	3.95e-66	220
k119_138398_3	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	36.1	341	349	706	2.34e-63	213
k119_138398_3	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	36.1	341	349	700	5.77e-63	211
k119_138398_3	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	36.1	341	349	700	5.82e-62	209
k119_138398_3	SARG|AAY67970	35.8	341	349	698	1.09e-61	208
k119_61365_4	SARG|CAB61224	40.7	123	128	297	9.06e-22	86.7
k119_61365_4	ResF|VanNXY_1_JF802084_2	38.8	116	128	133	1.10e-21	82.8
k119_61365_4	NCBI|WP_063856820.1|1|1|vanXY-N|vanXY-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-N|AMR|glycopeptide	38.8	116	128	190	4.21e-21	82.8
k119_61365_4	SARG|AAY52007	40.7	123	128	294	1.73e-20	83.2
k119_61365_4	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	40.7	123	128	296	1.77e-20	83.2
k119_61365_4	NCBI|WP_063856783.1|1|1|vanXY-G2|vanXY-G2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-G2|AMR|glycopeptide	35.5	121	128	254	5.27e-20	81.3
k119_61365_4	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	40.2	117	128	299	6.90e-20	81.6
k119_61365_4	NCBI|WP_008377360.1|1|1|vanXY-c4|vanXY-c4|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-C|AMR|glycopeptide	36.4	118	128	190	9.13e-20	79.3
k119_61365_4	SARG|ACP19238	39.8	123	128	296	1.29e-19	80.9
k119_61365_4	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	39.8	123	128	296	1.29e-19	80.9
k119_38886_4	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.8	361	373	718	9.77e-55	190
k119_13494_1	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.9	240	388	451	1.61e-27	112
k119_13494_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.5	200	388	381	9.06e-22	94.7
k119_13494_1	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.5	200	388	381	9.06e-22	94.7
k119_13494_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.9	201	388	381	5.69e-21	92.4
k119_13494_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.9	201	388	381	5.69e-21	92.4
k119_13494_1	CARD|gb|AEX49906.1|ARO:3003583|basS	27.2	235	388	477	9.64e-18	83.6
k119_13494_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.3	233	388	370	1.00e-17	82.8
k119_13494_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.3	233	388	365	5.80e-17	80.5
k119_13494_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	27.4	208	388	885	1.18e-15	77.8
k119_20115_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	60.5	433	432	1162	1.38e-178	528
k119_20115_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	60.0	433	432	1186	3.56e-174	518
k119_20115_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	60.0	433	432	1186	3.56e-174	518
k119_32892_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	55.6	270	312	362	5.20e-98	292
k119_32892_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	44.8	299	312	664	8.50e-81	256
k119_32892_1	SARG|gb|AAK76136.1|ARO:3000025|patB	43.3	307	312	588	1.23e-76	244
k119_32892_1	SARG|gi|748767925|ref|WP_040019608.1|	42.2	308	312	623	2.14e-74	239
k119_32892_1	SARG|gi|943909899|ref|WP_055545300.1|	39.8	304	312	601	3.74e-74	238
k119_32892_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	41.6	305	312	578	3.45e-73	234
k119_32892_1	SARG|gi|943938624|ref|WP_055567802.1|	39.5	304	312	602	8.06e-73	234
k119_32892_1	SARG|gi|817122037|ref|WP_046494699.1|	40.6	303	312	613	1.42e-72	234
k119_32892_1	SARG|gi|655401130|ref|WP_028800283.1|	40.3	305	312	599	1.49e-72	233
k119_32892_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	41.6	308	312	579	1.93e-72	233
k119_109776_16	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	24.7	283	610	380	7.89e-17	81.6
k119_109776_16	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.7	283	610	380	7.89e-17	81.6
k119_109776_16	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.2	267	610	370	2.40e-14	73.9
k119_109776_16	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	21.6	342	610	381	6.13e-14	72.8
k119_109776_16	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	21.6	342	610	381	6.13e-14	72.8
k119_109776_16	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	22.7	264	610	365	1.31e-13	71.6
k119_109776_16	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.2	343	610	381	4.57e-13	70.1
k119_109776_16	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.2	343	610	381	4.57e-13	70.1
k119_109776_16	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	21.9	342	610	381	8.11e-13	69.3
k119_109776_16	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	21.9	342	610	381	8.11e-13	69.3
k119_109776_17	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.0	187	199	231	1.97e-52	167
k119_109776_17	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.2	199	199	231	4.49e-51	163
k119_109776_17	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.2	199	199	231	6.35e-51	163
k119_109776_17	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.2	199	199	231	1.27e-50	162
k119_109776_17	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.2	199	199	231	1.27e-50	162
k119_109776_17	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.5	188	199	232	1.31e-50	162
k119_109776_17	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.5	188	199	232	1.31e-50	162
k119_109776_17	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.7	199	199	231	3.60e-50	161
k119_109776_17	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.9	191	199	235	2.29e-49	159
k119_109776_17	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.4	189	199	231	5.78e-49	158
k119_129231_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.9	222	235	255	6.82e-49	160
k119_129231_2	SARG|gb|AAV85982.1|ARO:3000535|macB	36.2	235	235	644	9.43e-47	162
k119_129231_2	SARG|gi|921979807|ref|WP_053271336.1|	36.5	222	235	648	6.87e-46	160
k119_129231_2	SARG|gi|895865878|ref|WP_048974758.1|	36.5	222	235	646	3.14e-43	153
k119_129231_2	SARG|gb|AAK76137.1|ARO:3000024|patA	30.2	222	235	564	4.54e-22	93.2
k119_129231_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.9	204	235	362	1.97e-14	70.5
k119_129231_2	SARG|gi|817536927|ref|WP_046586836.1|	24.6	179	235	492	3.53e-11	61.2
k119_129231_2	SARG|AJ579365.gene.p01	24.1	187	235	492	4.77e-11	60.8
k119_129231_2	SARG|gi|951389844|ref|WP_057765492.1|	25.7	175	235	492	2.12e-10	58.9
k119_129231_2	SARG|gi|517204321|ref|WP_018393139.1|	26.3	179	235	492	6.98e-10	57.4
k119_42477_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	27.1	642	618	885	3.69e-64	226
k119_42477_1	CARD|gb|ADM92606.1|ARO:3000549|adeS	26.4	201	618	361	1.30e-13	71.6
k119_42477_1	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	20.0	265	618	341	6.38e-10	60.1
k119_42477_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	49.6	115	136	225	1.13e-37	126
k119_42477_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	49.6	115	136	225	1.13e-37	126
k119_42477_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.3	126	136	219	3.87e-31	109
k119_42477_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.8	129	136	231	1.08e-26	98.6
k119_42477_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	37.4	131	136	247	2.96e-26	97.8
k119_42477_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.3	128	136	232	3.06e-26	97.4
k119_42477_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	35.1	131	136	231	4.22e-26	97.1
k119_42477_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.4	137	136	233	8.71e-26	96.3
k119_42477_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.8	128	136	229	1.13e-25	95.9
k119_42477_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.9	126	136	232	1.69e-25	95.5
k119_1508_2	SARG|NP_348076	21.7	230	243	652	5.07e-16	75.9
k119_1519_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.4	90	90	232	7.43e-24	89.4
k119_1519_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	45.3	86	90	232	1.47e-23	88.6
k119_1519_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.8	89	90	233	9.63e-21	81.3
k119_1519_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.7	86	90	231	9.98e-20	78.6
k119_1519_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.9	86	90	232	1.01e-19	78.6
k119_1519_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.2	88	90	239	1.59e-19	78.2
k119_1519_1	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.7	89	90	232	2.80e-19	77.4
k119_1519_1	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.7	89	90	232	2.80e-19	77.4
k119_1519_1	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.7	89	90	232	2.80e-19	77.4
k119_1519_1	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.7	89	90	232	2.80e-19	77.4
k119_113210_2	SARG|gi|500194536|ref|WP_011867743.1|	35.2	210	349	306	5.39e-28	110
k119_113210_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.8	211	349	343	6.26e-25	102
k119_113210_2	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	28.3	272	349	293	1.97e-15	74.7
k119_65343_1	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	37.9	206	196	444	3.35e-31	116
k119_1622_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.0	684	656	703	3.67e-158	471
k119_42773_1	CARD|gb|AAK37618.1|ARO:3005008|TxR	31.3	214	373	318	8.06e-21	90.9
k119_100356_5	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	29.0	238	260	343	1.04e-26	105
k119_100356_6	SARG|gi|695840638|ref|WP_032753940.1|	28.5	228	237	646	6.73e-20	87.0
k119_100356_6	SARG|gi|985815823|ref|WP_060876116.1|	28.1	228	237	646	3.08e-19	85.1
k119_100356_6	SARG|YP_002239469	28.1	228	237	646	3.08e-19	85.1
k119_100356_6	SARG|gi|556492128|ref|WP_023339842.1|	28.1	228	237	646	3.08e-19	85.1
k119_100356_6	SARG|gi|765031087|ref|WP_044596899.1|	29.8	225	237	646	4.17e-19	84.7
k119_100356_6	SARG|gi|782756348|ref|WP_045630015.1|	29.4	221	237	646	4.17e-19	84.7
k119_100356_6	SARG|gi|983405167|ref|WP_060572706.1|	31.0	226	237	646	4.17e-19	84.7
k119_100356_6	SARG|gi|754493745|ref|WP_041910640.1|	31.0	226	237	646	5.65e-19	84.3
k119_100356_6	SARG|gi|895898290|ref|WP_048999361.1|	31.0	226	237	646	5.65e-19	84.3
k119_100356_6	SARG|gi|896106549|ref|WP_049136608.1|	29.4	221	237	646	5.65e-19	84.3
k119_97438_2	SARG|gi|507086196|ref|WP_016156937.1|	33.8	210	245	648	8.79e-24	98.6
k119_97438_2	SARG|gi|757799695|ref|WP_043016897.1|	33.8	210	245	648	1.19e-23	98.2
k119_97438_2	SARG|gi|1045891604|ref|WP_065554100.1|	33.8	210	245	648	1.19e-23	98.2
k119_97438_2	SARG|gi|507082903|ref|WP_016153652.1|	33.8	210	245	648	1.19e-23	98.2
k119_97438_2	SARG|gi|922960663|ref|WP_053388845.1|	33.8	210	245	648	1.19e-23	98.2
k119_97438_2	SARG|gi|896325272|ref|WP_049294291.1|	35.4	209	245	648	1.19e-23	98.2
k119_97438_2	SARG|gi|835233765|ref|WP_047410073.1|	33.8	210	245	648	1.62e-23	97.8
k119_97438_2	SARG|gi|740856590|ref|WP_038641842.1|	33.3	210	245	648	5.49e-23	96.3
k119_97438_2	SARG|gi|754951242|ref|WP_042307417.1|	33.3	210	245	648	7.44e-23	95.9
k119_97438_2	SARG|gi|493734654|ref|WP_006683876.1|	33.3	210	245	648	7.44e-23	95.9
k119_14035_6	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	33.3	78	79	491	1.18e-06	43.1
k119_94396_1	SARG|gb|AAV85982.1|ARO:3000535|macB	36.5	312	328	644	2.77e-55	189
k119_94396_1	SARG|gi|803568669|ref|WP_046077412.1|	37.5	288	328	648	2.11e-54	187
k119_94396_1	SARG|gi|446110352|ref|WP_000188207.1|	37.5	288	328	648	2.11e-54	187
k119_94396_1	SARG|YP_002382193	37.5	288	328	648	2.11e-54	187
k119_94396_1	SARG|gi|803575554|ref|WP_046081557.1|	37.5	288	328	648	2.11e-54	187
k119_94396_1	SARG|gi|446110351|ref|WP_000188206.1|	37.5	288	328	648	2.11e-54	187
k119_94396_1	SARG|gi|495736522|ref|WP_008461101.1|	37.5	288	328	648	4.06e-54	186
k119_94396_1	SARG|gi|555268367|ref|WP_023249730.1|	39.4	289	328	648	4.06e-54	186
k119_94396_1	SARG|gi|1027935297|ref|WP_063809363.1|	39.4	289	328	648	4.06e-54	186
k119_94396_1	SARG|gi|746253210|ref|WP_039301529.1|	37.5	288	328	648	5.64e-54	186
k119_20639_1	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	32.9	347	556	1186	1.24e-50	186
k119_20639_1	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	32.9	347	556	1186	1.24e-50	186
k119_20639_1	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	32.6	371	556	1162	1.01e-45	172
k119_65645_2	SARG|ZP_03958019	68.5	130	145	317	1.02e-52	168
k119_65645_2	SARG|YP_002937728	73.8	126	145	289	7.76e-52	165
k119_65645_2	SARG|YP_002929946	66.2	130	145	282	4.11e-50	160
k119_65645_2	SARG|ZP_04528247	68.9	132	145	279	1.07e-49	159
k119_65645_2	SARG|ZP_03984017	56.8	132	145	288	4.18e-39	132
k119_65645_2	SARG|ZP_04433866	56.8	132	145	288	8.31e-39	131
k119_65645_2	SARG|ZP_03949893	57.7	130	145	288	1.17e-38	131
k119_65645_2	SARG|ZP_03945515	56.2	137	145	291	1.25e-38	131
k119_65645_2	SARG|ZP_03938934	53.3	137	145	288	3.99e-36	124
k119_65645_2	SARG|ZP_03941859	52.6	137	145	288	1.57e-35	123
k119_1934_4	SARG|gb|CAE00499.1|ARO:3003835|cdeA	28.4	426	460	441	1.42e-41	152
k119_1934_4	SARG|gi|505177635|ref|WP_015364737.1|	25.5	423	460	451	3.47e-36	137
k119_1934_4	SARG|ZP_04679156	26.2	423	460	451	4.77e-36	137
k119_1934_4	SARG|gi|488374619|ref|WP_002444004.1|	25.4	426	460	452	9.15e-36	136
k119_1934_4	SARG|HE999704.1.gene3064.p01	36.1	208	460	241	2.32e-35	130
k119_1934_4	SARG|gi|446573718|ref|WP_000651064.1|	27.1	425	460	451	2.16e-34	132
k119_1934_4	SARG|gi|686155635|ref|WP_031787393.1|	26.6	425	460	451	4.07e-34	132
k119_1934_4	SARG|gi|686123390|ref|WP_031769354.1|	27.8	436	460	451	1.05e-33	130
k119_1934_4	SARG|gi|565830932|ref|WP_023914633.1|	27.4	434	460	451	1.44e-33	130
k119_1934_4	SARG|gi|516415429|ref|WP_017804827.1|	27.5	436	460	451	2.71e-33	129
k119_10956_1	SARG|gb|ADZ12699.1|ARO:3005091|RanA	39.7	73	124	258	3.88e-08	48.9
k119_87860_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.8	282	390	1024	6.63e-07	50.4
k119_87860_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.8	282	390	1024	6.63e-07	50.4
k119_87860_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.8	282	390	1024	6.63e-07	50.4
k119_87860_1	SARG|gb|CAA53189|ARO:3000521|mupA	24.8	282	390	1024	6.63e-07	50.4
k119_116542_3	SARG|ZP_04679156	24.0	429	445	451	1.61e-24	104
k119_116542_3	SARG|gi|505177635|ref|WP_015364737.1|	24.0	429	445	451	7.26e-24	102
k119_116542_3	SARG|gi|686355454|ref|WP_031890196.1|	23.2	427	445	451	1.79e-23	101
k119_116542_3	SARG|gi|565830932|ref|WP_023914633.1|	23.4	428	445	451	2.42e-23	100
k119_116542_3	SARG|gi|446573700|ref|WP_000651046.1|	23.4	428	445	451	2.42e-23	100
k119_116542_3	SARG|gi|686123390|ref|WP_031769354.1|	23.4	428	445	451	3.26e-23	100
k119_116542_3	SARG|gi|686448604|ref|WP_031928572.1|	23.1	428	445	451	3.26e-23	100
k119_116542_3	SARG|gi|486215009|ref|WP_001556470.1|	23.4	428	445	451	3.26e-23	100
k119_116542_3	SARG|gi|537465183|ref|WP_020976941.1|	23.1	428	445	451	4.40e-23	100
k119_116542_3	SARG|gi|763462741|ref|WP_044292157.1|	23.4	428	445	451	4.40e-23	100
k119_45916_1	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	35.6	202	269	481	1.84e-35	131
k119_45916_1	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	35.6	202	269	451	3.36e-35	130
k119_45916_1	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	34.5	197	269	451	1.22e-33	125
k119_56049_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.7	587	700	1024	3.13e-44	170
k119_56049_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.7	587	700	1024	3.13e-44	170
k119_56049_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.7	587	700	1024	9.97e-44	168
k119_56049_1	SARG|gb|CAA53189|ARO:3000521|mupA	22.7	587	700	1024	9.97e-44	168
k119_113802_4	SARG|gi|505420018|ref|WP_015607120.1|	29.8	215	251	603	5.91e-21	90.5
k119_113802_4	SARG|gi|739906046|ref|WP_037756452.1|	29.8	225	251	620	5.01e-20	87.8
k119_113802_4	SARG|gi|516574297|ref|WP_017949361.1|	29.8	225	251	620	5.01e-20	87.8
k119_113802_4	SARG|gi|947982677|ref|WP_056642336.1|	28.7	223	251	626	5.04e-20	87.8
k119_113802_4	SARG|gi|639892676|ref|WP_024755698.1|	28.7	223	251	631	5.05e-20	87.8
k119_113802_4	SARG|gi|695842130|ref|WP_032755430.1|	29.4	214	251	603	6.71e-20	87.4
k119_113802_4	SARG|gi|817122037|ref|WP_046494699.1|	28.0	225	251	613	6.76e-20	87.4
k119_113802_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.9	229	251	575	8.87e-20	87.0
k119_113802_4	SARG|gi|664244930|ref|WP_030776974.1|	30.0	227	251	601	9.07e-20	87.0
k119_113802_4	SARG|gi|944152509|ref|WP_055644808.1|	28.7	223	251	616	9.17e-20	87.0
k119_142679_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	26.9	264	383	323	2.82e-17	80.9
k119_142679_2	SARG|DQ018711.1.gene4.p01	31.0	203	383	322	3.79e-17	80.5
k119_142679_2	SARG|Q47748	26.9	264	383	323	5.18e-17	80.1
k119_142679_2	SARG|YP_002333394	26.9	264	383	323	7.01e-17	79.7
k119_142679_2	SARG|gi|498515089|ref|WP_010815296.1|	26.9	264	383	323	1.28e-16	79.0
k119_142679_2	SARG|gi|985522333|ref|WP_060811962.1|	26.9	264	383	323	1.28e-16	79.0
k119_142679_2	SARG|AF310956.2.gene5.p01	26.5	264	383	323	2.35e-16	78.2
k119_142679_2	SARG|gi|738848198|ref|WP_036737307.1|	30.5	203	383	323	2.35e-16	78.2
k119_142679_2	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	26.5	264	383	323	2.35e-16	78.2
k119_142679_2	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	27.7	238	383	314	9.70e-16	76.3
k119_142679_5	SARG|gb|APB03219.1|ARO:3003986|TaeA	45.2	485	468	648	3.58e-128	385
k119_142679_5	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	404	468	655	3.52e-52	185
k119_142679_5	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	404	468	655	3.52e-52	185
k119_142679_5	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	404	468	655	3.36e-51	182
k119_142679_5	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	404	468	655	4.63e-51	182
k119_142679_5	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	404	468	655	4.63e-51	182
k119_142679_5	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	404	468	655	4.63e-51	182
k119_142679_5	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	404	468	655	4.63e-51	182
k119_142679_5	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.2	404	468	655	4.63e-51	182
k119_142679_5	SARG|gb|AKA86814|ARO:3003746|optrA	32.2	404	468	655	4.63e-51	182
k119_120145_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.5	123	513	370	8.71e-07	50.1
k119_120145_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.6	127	513	365	3.52e-06	48.1
k119_120145_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	54.5	44	47	231	4.74e-11	53.5
k119_120145_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	52.3	44	47	230	2.41e-10	51.6
k119_120145_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	61.8	34	47	232	1.71e-09	49.3
k119_120145_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	61.8	34	47	232	1.71e-09	49.3
k119_120145_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	55.6	45	47	231	3.26e-09	48.5
k119_120145_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	55.6	45	47	231	3.26e-09	48.5
k119_120145_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	61.8	34	47	231	5.94e-08	45.1
k119_120145_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	61.8	34	47	231	5.94e-08	45.1
k119_120145_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	61.8	34	47	231	5.94e-08	45.1
k119_120145_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	56.3	32	47	231	1.06e-06	41.6
k119_30304_2	SARG|FJ349556.1.gene4.p01	26.3	156	347	233	1.82e-10	59.3
k119_30304_2	NCBI|WP_107309513.1|1|1|vanY-M|vanY-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-M|AMR|glycopeptide	26.3	156	347	287	2.99e-10	59.3
k119_30304_2	SARG|ACP19238	30.3	122	347	296	1.85e-09	57.0
k119_30304_2	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	30.3	122	347	296	1.85e-09	57.0
k119_30304_2	SARG|AAA65958	30.3	122	347	303	1.93e-09	57.0
k119_30304_2	SARG|gi|503204183|ref|WP_013438844.1|	30.3	122	347	303	1.93e-09	57.0
k119_30304_2	SARG|gi|309385867|gb|ADO66792.1|	30.3	122	347	305	1.95e-09	57.0
k119_30304_2	SARG|gi|816206780|gb|AKE81065.1|	30.3	122	347	327	2.17e-09	57.0
k119_30304_2	SARG|CAB61224	29.5	122	347	297	3.34e-09	56.2
k119_30304_2	SARG|AAY52007	29.3	123	347	294	4.41e-09	55.8
k119_91649_9	CARD|gb|BAB36671.1|ARO:3000832|evgA	22.9	205	220	204	7.73e-13	63.9
k119_91649_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.0	103	220	231	2.89e-12	62.8
k119_91649_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	25.0	212	220	229	2.36e-10	57.4
k119_91649_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.3	119	220	219	1.02e-09	55.5
k119_91649_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	27.4	124	220	235	7.62e-09	53.1
k119_91649_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.5	113	220	228	1.34e-08	52.4
k119_62691_2	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	43.0	79	112	346	9.14e-15	67.4
k119_5151_1	SARG|gb|AAK76136.1|ARO:3000025|patB	39.7	501	502	588	2.93e-105	325
k119_5151_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.5	501	502	664	1.62e-95	302
k119_5151_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	40.8	375	502	362	3.06e-84	263
k119_5151_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.0	503	502	579	1.53e-76	250
k119_5151_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.5	501	502	582	6.29e-76	248
k119_5151_1	SARG|gi|695865802|ref|WP_032778631.1|	31.7	502	502	605	7.51e-76	249
k119_5151_1	SARG|gi|497748188|ref|WP_010062372.1|	31.3	502	502	605	2.88e-75	247
k119_5151_1	SARG|gi|944152509|ref|WP_055644808.1|	30.8	506	502	616	3.65e-75	247
k119_5151_1	SARG|gi|695887424|ref|WP_032788534.1|	31.3	499	502	605	4.03e-75	247
k119_5151_1	SARG|gi|664180077|ref|WP_030714054.1|	31.1	501	502	605	4.03e-75	247
k119_33794_1	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	32.9	152	159	641	4.19e-19	82.0
k119_33794_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.4	249	256	255	1.29e-81	244
k119_33794_2	SARG|gi|823326845|ref|WP_047080664.1|	41.2	221	256	648	1.54e-54	184
k119_33794_2	SARG|gi|823302270|ref|WP_047057473.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|976146774|ref|WP_059305359.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|1022664304|ref|WP_063420886.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|895981299|ref|WP_049056431.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|823309640|ref|WP_047064288.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|823281237|ref|WP_047037467.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|505807117|ref|WP_015704872.1|	41.2	221	256	648	2.98e-54	184
k119_33794_2	SARG|gi|895967513|ref|WP_049046752.1|	41.2	221	256	648	2.98e-54	184
k119_33794_3	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	46.8	111	116	341	2.42e-27	101
k119_120452_2	SARG|gi|585358510|ref|WP_024240108.1|	43.1	51	53	648	3.39e-08	46.2
k119_120452_2	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	32.1	53	53	494	2.01e-06	41.2
k119_120452_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.4	48	53	664	3.79e-06	40.4
k119_82073_1	SARG|gb|AAD12162.1|ARO:3001299|tlrB	33.0	188	192	280	3.16e-26	100
k119_82073_1	SARG|gb|CAB37345.2|ARO:3004592|erm(32)	33.0	188	192	280	3.16e-26	100
k119_82073_1	SARG|gb|AAS79458.1|ARO:3001302|chrB	32.4	185	192	280	7.05e-22	89.0
k119_82073_1	megares|MEG_4106|Drugs|MLS|23S_rRNA_methyltransferases|MYRA_1	27.9	204	192	295	3.17e-18	79.3
k119_82073_1	SARG|gb|BAA03674.1|ARO:3001300|myrA	27.9	204	192	295	3.17e-18	79.3
k119_46280_1	SARG|L42544.gene.p01	50.0	116	131	651	1.74e-32	119
k119_46280_1	SARG|AAV80410	50.0	116	131	651	1.74e-32	119
k119_46280_1	SARG|ACI02041	50.0	116	131	639	1.53e-31	116
k119_46280_1	SARG|NP_348076	50.9	116	131	652	1.57e-31	116
k119_46280_1	megares|MEG_7167|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	49.1	116	131	639	2.09e-31	115
k119_46280_1	SARG|YP_594556	50.9	116	131	639	2.87e-31	115
k119_46280_1	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	49.1	116	131	629	3.85e-31	115
k119_46280_1	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	49.1	116	131	629	3.85e-31	115
k119_46280_1	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	49.1	116	131	629	3.85e-31	115
k119_46280_1	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	49.1	116	131	629	3.85e-31	115
k119_21262_1	SARG|gi|1035706844|ref|WP_064548272.1|	31.0	84	950	648	5.64e-07	52.4
k119_85144_5	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.9	213	328	255	1.67e-31	117
k119_85144_5	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.1	223	328	258	7.22e-26	102
k119_85144_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.8	143	281	255	1.96e-15	73.2
k119_85144_6	SARG|gi|974672242|ref|WP_059256507.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|974641719|ref|WP_059227752.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|643601187|ref|WP_025237288.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|974628291|ref|WP_059215695.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|446110298|ref|WP_000188153.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|446110299|ref|WP_000188154.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|ZP_02903696	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|974633183|ref|WP_059219858.1|	32.7	171	281	648	6.26e-15	73.6
k119_85144_6	SARG|gi|974684692|ref|WP_059267998.1|	32.7	171	281	648	6.26e-15	73.6
k119_126915_3	CARD|gb|AAC75429.1|ARO:3000833|evgS	25.9	166	171	1197	3.12e-16	74.3
k119_126915_3	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.2	114	171	223	9.76e-14	65.5
k119_126915_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.6	107	171	232	2.04e-12	62.0
k119_126915_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	29.7	128	171	231	3.86e-12	61.2
k119_126915_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.3	128	171	247	1.18e-11	60.1
k119_126915_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.3	123	171	219	2.35e-11	58.9
k119_126915_3	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	28.8	118	171	225	2.38e-10	56.2
k119_126915_3	CARD|gb|AAC73788.1|ARO:3003841|kdpE	28.8	118	171	225	2.38e-10	56.2
k119_126915_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	26.9	108	171	232	3.21e-09	53.1
k119_126915_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	26.9	108	171	232	3.21e-09	53.1
k119_126915_4	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.8	223	314	359	2.06e-16	77.8
k119_126915_4	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.4	222	314	364	6.50e-14	70.5
k119_126915_4	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.4	222	314	364	6.50e-14	70.5
k119_21438_2	SARG|HE999704.1.gene3064.p01	24.1	241	428	241	9.27e-18	81.3
k119_21438_2	SARG|gi|441475675|emb|CCQ25429.1|	26.8	183	428	211	7.91e-11	60.5
k119_24312_1	SARG|gi|944470764|ref|WP_055701183.1|	38.9	72	78	601	1.43e-08	48.5
k119_24312_1	SARG|gi|928900436|ref|WP_053931243.1|	37.5	72	78	600	1.96e-08	48.1
k119_24312_1	SARG|gi|664579989|ref|WP_031094015.1|	37.5	72	78	601	1.96e-08	48.1
k119_24312_1	SARG|gb|AAK76136.1|ARO:3000025|patB	33.3	78	78	588	2.68e-08	47.8
k119_24312_1	SARG|gi|943896259|ref|WP_055534530.1|	36.1	72	78	601	2.68e-08	47.8
k119_24312_1	SARG|gi|664244930|ref|WP_030776974.1|	36.1	72	78	601	3.66e-08	47.4
k119_24312_1	SARG|gi|1011969930|ref|WP_062776015.1|	36.1	72	78	601	3.66e-08	47.4
k119_24312_1	SARG|gi|943938624|ref|WP_055567802.1|	36.1	72	78	602	3.66e-08	47.4
k119_24312_1	SARG|gi|947982677|ref|WP_056642336.1|	36.1	72	78	626	5.02e-08	47.0
k119_24312_1	SARG|gi|639892676|ref|WP_024755698.1|	36.1	72	78	631	5.02e-08	47.0
k119_24312_2	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.0	236	273	578	1.88e-24	101
k119_24312_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.0	196	273	362	3.07e-19	85.1
k119_24312_2	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	29.4	211	273	505	1.97e-15	74.7
k119_24312_2	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	27.6	217	273	504	3.89e-14	70.9
k119_24312_2	SARG|gb|AVI44920.1|ARO:3004470|poxtA	24.8	214	273	542	1.79e-13	68.9
k119_24312_2	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	24.8	214	273	544	1.79e-13	68.9
k119_24312_2	SARG|gb|AGN74946|ARO:3003749|salA	29.9	194	273	541	1.92e-12	65.9
k119_24312_2	SARG|gi|490350160|ref|WP_004229933.1|	25.4	197	273	493	6.32e-11	61.2
k119_24312_2	SARG|gi|937111451|ref|WP_054550161.1|	25.4	197	273	493	8.48e-11	60.8
k119_24312_2	SARG|gi|860350489|ref|WP_048392759.1|	25.4	197	273	493	1.14e-10	60.5
k119_30845_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	52.6	78	121	648	3.22e-22	89.4
k119_30845_1	SARG|gi|494215524|ref|WP_007131565.1|	34.3	102	121	492	2.28e-10	55.5
k119_30845_1	SARG|U82085.gene.p01	41.4	70	121	552	4.31e-10	54.7
k119_30845_1	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	32.0	75	121	494	1.08e-09	53.5
k119_30845_1	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	33.7	98	121	524	1.48e-09	53.1
k119_30845_1	SARG|FR772051.1.gene9.p01	34.1	85	121	524	2.75e-09	52.4
k119_30845_1	SARG|gi|558693259|ref|WP_023522676.1|	30.4	102	121	492	5.07e-09	51.6
k119_30845_1	SARG|gi|951389844|ref|WP_057765492.1|	32.2	90	121	492	5.07e-09	51.6
k119_30845_1	SARG|gi|445983946|ref|WP_000061801.1|	30.4	102	121	492	5.07e-09	51.6
k119_30845_1	SARG|gi|445983947|ref|WP_000061802.1|	30.4	102	121	492	6.91e-09	51.2
k119_5625_9	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.8	211	273	293	3.00e-16	75.9
k119_5625_9	SARG|gb|AAK76137.1|ARO:3000024|patA	24.9	217	273	564	7.31e-09	55.1
k119_5625_9	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.4	201	273	550	5.66e-06	46.2
k119_143175_2	SARG|gb|AAK76137.1|ARO:3000024|patA	34.4	573	577	564	6.92e-102	318
k119_143175_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.3	535	577	575	2.34e-94	299
k119_143175_2	SARG|gi|1045390184|ref|WP_065479071.1|	29.3	580	577	605	4.47e-68	230
k119_143175_2	SARG|gi|497748188|ref|WP_010062372.1|	29.1	580	577	605	1.68e-67	229
k119_143175_2	SARG|gi|501350226|ref|WP_012381861.1|	29.5	580	577	603	2.25e-67	228
k119_143175_2	SARG|gi|503923650|ref|WP_014157644.1|	37.2	366	577	601	3.00e-67	228
k119_143175_2	SARG|gi|664556405|ref|WP_031071225.1|	29.1	580	577	602	3.06e-67	228
k119_143175_2	SARG|gi|664170108|ref|WP_030704355.1|	29.5	580	577	603	3.12e-67	228
k119_143175_2	SARG|gi|490068471|ref|WP_003970646.1|	29.5	580	577	603	3.12e-67	228
k119_143175_2	SARG|gi|664352659|ref|WP_030880307.1|	37.2	366	577	601	4.18e-67	228
k119_136842_2	SARG|gb|ATL63235.1|ARO:3004357|catV	38.8	206	218	219	3.65e-55	174
k119_136842_2	SARG|YP_001144149	39.9	208	218	208	1.93e-52	167
k119_136842_2	NCBI|WP_043774378.1|1|1|catA13|catA13|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_A-13_phenicol_O-acetyltransferase|AMR|phenicol	39.8	206	218	207	7.52e-52	165
k119_136842_2	SARG|M35190.gene.p01	38.3	206	218	207	1.71e-50	162
k119_136842_2	megares|MEG_8014|Drugs|Phenicol|Chloramphenicol_acetyltransferases|CATT_1	36.9	206	218	219	3.60e-44	146
k119_136842_2	SARG|YP_002150494	34.4	212	218	217	3.82e-43	143
k119_136842_2	SARG|S48276.1.gene1.p01	34.6	205	218	216	5.25e-43	143
k119_136842_2	SARG|AF226276.1.gene3.p01	33.7	205	218	207	4.58e-42	140
k119_136842_2	SARG|P00484	33.7	205	218	213	1.53e-41	139
k119_136842_2	SARG|AJ249249.1.gene5.p01	33.7	205	218	213	1.53e-41	139
k119_40605_3	SARG|gi|542061059|gb|ERI11611.1|	29.7	256	260	316	1.30e-17	79.7
k119_40605_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.6	209	260	307	1.48e-16	76.6
k119_40605_3	SARG|ZP_04081918	27.8	259	260	306	5.16e-16	75.1
k119_40605_3	SARG|gi|447195835|ref|WP_001273091.1|	28.4	236	260	306	1.80e-15	73.6
k119_40605_3	SARG|gi|447195836|ref|WP_001273092.1|	28.4	236	260	306	3.37e-15	72.8
k119_40605_3	SARG|gi|500194536|ref|WP_011867743.1|	29.0	193	260	306	1.02e-13	68.6
k119_101607_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.1	91	487	231	3.44e-12	65.1
k119_101607_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.1	88	487	232	9.46e-11	60.8
k119_101607_1	CARD|gb|AAG06465.1|ARO:3005063|cprR	42.0	69	487	223	1.09e-07	51.6
k119_101607_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.0	87	487	219	1.50e-06	48.1
k119_108258_2	SARG|gi|505177635|ref|WP_015364737.1|	24.5	216	230	451	4.33e-16	75.5
k119_108258_2	SARG|ZP_04679156	24.3	218	230	451	1.99e-15	73.6
k119_108258_2	SARG|gi|488374619|ref|WP_002444004.1|	23.5	213	230	452	1.99e-15	73.6
k119_108265_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.7	219	674	364	8.47e-12	66.2
k119_108265_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.7	219	674	364	8.47e-12	66.2
k119_108265_1	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	21.2	217	674	359	2.39e-08	55.5
k119_46831_3	SARG|gi|751930065|ref|WP_041144773.1|	40.5	227	247	648	1.79e-43	154
k119_46831_3	SARG|gi|803568669|ref|WP_046077412.1|	38.7	230	247	648	2.34e-42	151
k119_46831_3	SARG|gi|446110352|ref|WP_000188207.1|	38.7	230	247	648	2.34e-42	151
k119_46831_3	SARG|YP_002382193	38.7	230	247	648	2.34e-42	151
k119_46831_3	SARG|gi|803575554|ref|WP_046081557.1|	38.7	230	247	648	2.34e-42	151
k119_46831_3	SARG|gi|446110351|ref|WP_000188206.1|	38.7	230	247	648	2.34e-42	151
k119_46831_3	SARG|gi|754964360|ref|WP_042320280.1|	40.2	224	247	648	4.45e-42	150
k119_46831_3	SARG|gi|751264306|ref|WP_040974017.1|	40.4	225	247	646	1.58e-41	149
k119_46831_3	SARG|gi|757782629|ref|WP_043001213.1|	39.0	231	247	648	1.60e-41	149
k119_46831_3	SARG|gi|763407609|ref|WP_044264203.1|	39.0	231	247	648	1.60e-41	149
k119_57141_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	436	429	655	3.96e-95	298
k119_57141_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	436	429	655	3.96e-95	298
k119_57141_1	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	5.57e-95	298
k119_57141_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	7.83e-95	297
k119_57141_1	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	7.83e-95	297
k119_57141_1	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	1.10e-94	297
k119_57141_1	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	1.10e-94	297
k119_57141_1	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	1.10e-94	297
k119_57141_1	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	1.10e-94	297
k119_57141_1	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.6	436	429	655	1.10e-94	297
k119_63317_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	46.8	449	456	575	1.76e-130	388
k119_63317_1	SARG|gb|AAK76137.1|ARO:3000024|patA	35.3	445	456	564	9.77e-88	277
k119_63317_1	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.6	396	456	579	1.73e-54	190
k119_63317_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.2	444	456	582	2.52e-54	189
k119_63317_1	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.3	396	456	579	8.82e-53	185
k119_63317_1	SARG|gi|648667297|ref|WP_026359044.1|	30.7	384	456	605	3.42e-51	181
k119_63317_1	SARG|gi|501350226|ref|WP_012381861.1|	30.3	379	456	603	1.22e-50	180
k119_63317_1	SARG|gi|695842130|ref|WP_032755430.1|	30.6	379	456	603	3.22e-50	179
k119_63317_1	SARG|gi|505420018|ref|WP_015607120.1|	30.6	379	456	603	3.22e-50	179
k119_63317_1	SARG|gi|702897513|ref|WP_033300957.1|	30.2	378	456	601	4.33e-50	178
k119_63317_2	SARG|gb|AAK76136.1|ARO:3000025|patB	36.6	584	613	588	2.18e-125	381
k119_63317_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	50.9	330	613	362	1.04e-108	330
k119_63317_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.5	516	613	664	1.58e-107	337
k119_63317_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.9	581	613	582	3.31e-96	305
k119_63317_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	32.4	587	613	579	1.79e-94	300
k119_63317_2	SARG|gi|695842130|ref|WP_032755430.1|	32.2	518	613	603	9.22e-94	299
k119_63317_2	SARG|gi|505420018|ref|WP_015607120.1|	32.2	518	613	603	9.22e-94	299
k119_63317_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.6	591	613	579	2.70e-93	297
k119_63317_2	SARG|gi|1045390184|ref|WP_065479071.1|	32.0	516	613	605	2.04e-92	296
k119_63317_2	SARG|gi|944009777|ref|WP_055601444.1|	32.1	526	613	628	3.62e-92	296
k119_57208_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	49.5	574	580	575	6.78e-191	547
k119_57208_2	SARG|gb|AAK76137.1|ARO:3000024|patA	32.5	520	580	564	5.71e-83	269
k119_57208_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.0	520	580	664	1.94e-62	216
k119_57208_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.2	573	580	582	2.24e-61	212
k119_57208_2	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.0	585	580	574	5.10e-60	208
k119_57208_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.4	573	580	579	1.89e-55	196
k119_57208_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.4	573	580	579	1.83e-54	193
k119_57208_2	SARG|gi|928900436|ref|WP_053931243.1|	29.2	538	580	600	2.60e-54	193
k119_57208_2	SARG|gi|664579989|ref|WP_031094015.1|	29.2	538	580	601	2.64e-54	193
k119_57208_2	SARG|gb|AAK76136.1|ARO:3000025|patB	28.1	530	580	588	2.04e-53	190
k119_57208_3	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.2	169	277	582	1.01e-14	72.8
k119_57208_3	SARG|gi|664556405|ref|WP_031071225.1|	25.4	134	277	602	1.83e-09	57.0
k119_57208_3	SARG|gi|663350985|ref|WP_030349761.1|	24.6	134	277	613	1.89e-08	53.9
k119_57208_3	SARG|gi|664317010|ref|WP_030845774.1|	25.9	116	277	605	2.52e-08	53.5
k119_57208_3	SARG|gi|926286457|ref|WP_053623344.1|	25.9	116	277	605	2.52e-08	53.5
k119_57208_3	SARG|gi|663286402|ref|WP_030292859.1|	25.9	116	277	605	2.52e-08	53.5
k119_57208_3	SARG|gi|663342223|ref|WP_030341347.1|	25.9	116	277	605	2.52e-08	53.5
k119_57208_3	SARG|gi|662175949|ref|WP_030118884.1|	25.9	116	277	605	2.52e-08	53.5
k119_57208_3	SARG|gi|663155409|ref|WP_030194633.1|	25.9	116	277	605	2.52e-08	53.5
k119_57208_3	SARG|gi|664538723|ref|WP_031054357.1|	25.9	116	277	605	2.52e-08	53.5
k119_114731_1	SARG|gi|944470764|ref|WP_055701183.1|	25.4	291	295	601	1.72e-15	75.5
k119_114731_1	SARG|gi|943938624|ref|WP_055567802.1|	24.7	291	295	602	1.02e-14	73.2
k119_114731_1	SARG|gi|655401130|ref|WP_028800283.1|	24.5	290	295	599	1.84e-14	72.4
k119_114731_1	SARG|gi|516574297|ref|WP_017949361.1|	24.0	292	295	620	2.51e-14	72.0
k119_114731_1	SARG|gi|930482089|ref|WP_054228897.1|	23.9	289	295	599	3.32e-14	71.6
k119_114731_1	SARG|gi|985844137|ref|WP_060895163.1|	23.9	289	295	599	3.32e-14	71.6
k119_114731_1	SARG|gi|493394434|ref|WP_006350564.1|	24.2	302	295	602	3.33e-14	71.6
k119_114731_1	SARG|gi|517787730|ref|WP_018957938.1|	23.9	289	295	610	4.50e-14	71.2
k119_114731_1	SARG|gi|664244930|ref|WP_030776974.1|	24.4	291	295	601	6.00e-14	70.9
k119_114731_1	SARG|gi|748767925|ref|WP_040019608.1|	23.2	289	295	623	6.10e-14	70.9
k119_85641_1	SARG|YP_002850805	37.0	343	311	652	2.55e-54	186
k119_85641_1	SARG|ZP_02952732	37.0	343	311	652	4.89e-53	182
k119_85641_1	SARG|L20800.gene.p01	37.0	343	311	652	4.89e-53	182
k119_85641_1	SARG|ZP_02632674	37.0	343	311	660	5.41e-53	182
k119_85641_1	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	38.1	318	311	629	6.97e-52	179
k119_85641_1	ResF|tet(O/W)_2_AM889119_1	38.1	318	311	639	7.93e-52	179
k119_85641_1	SARG|ABN79417	38.1	318	311	639	4.08e-51	177
k119_85641_1	SARG|CAL69903	36.0	317	311	639	4.08e-51	177
k119_85641_1	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	37.7	318	311	629	4.99e-51	177
k119_85641_1	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	37.7	318	311	629	4.99e-51	177
k119_53962_1	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	35.6	351	348	379	1.03e-57	190
k119_53962_1	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	35.6	351	348	416	2.55e-57	190
k119_53962_1	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	34.3	338	348	349	4.76e-54	180
k119_53962_1	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	34.3	338	348	349	6.69e-54	179
k119_53962_1	SARG|gb|AIX48090.1|ARO:3004599|clcD	34.0	338	348	349	1.86e-53	178
k119_53962_3	CARD|gb|WKR28567.1|ARO:3007678|IreK	54.8	93	98	718	6.11e-29	107
k119_18182_1	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	47.0	198	198	223	1.68e-59	184
k119_18182_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.8	192	198	228	3.67e-26	99.4
k119_18182_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	199	198	219	1.64e-25	97.4
k119_18182_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	199	198	219	2.31e-25	97.1
k119_18182_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	199	198	220	2.36e-25	97.1
k119_18182_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	199	198	220	2.36e-25	97.1
k119_18182_1	SARG|ZP_02848503	29.5	200	198	221	1.40e-23	92.4
k119_18182_1	CARD|gb|BAB36671.1|ARO:3000832|evgA	23.8	185	198	204	8.40e-07	46.6
k119_18182_2	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	27.3	128	217	341	1.09e-13	67.8
k119_92868_1	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	25.0	164	178	343	9.07e-12	61.2
k119_92868_1	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	30.4	92	178	550	1.99e-09	54.7
k119_92868_1	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	32.5	83	178	568	1.40e-07	49.3
k119_92868_1	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	32.9	79	178	461	1.80e-07	48.9
k119_92868_1	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	32.9	79	178	461	1.80e-07	48.9
k119_92868_1	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	31.5	92	178	522	9.34e-06	43.9
k119_92868_1	SARG|DQ823382.1.gene1.p01	31.5	92	178	522	9.34e-06	43.9
k119_92868_1	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	31.5	92	178	522	9.34e-06	43.9
k119_92868_1	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	31.5	92	178	522	9.34e-06	43.9
k119_92868_1	SARG|AAF24091	31.5	92	178	522	9.34e-06	43.9
k119_105521_3	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	24.6	260	290	304	4.30e-12	64.3
k119_54216_3	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	38.8	152	160	164	1.77e-38	127
k119_54216_3	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	38.4	138	160	167	4.70e-31	108
k119_54216_3	megares|MEG_8062|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	35.1	168	160	195	3.89e-30	107
k119_54216_3	SARG|gb|WP_000949574.1|ARO:3005348|DfrA36	35.1	168	160	195	3.89e-30	107
k119_54216_3	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	37.2	164	160	166	4.11e-29	103
k119_54216_3	SARG|gb|BAE15963.1|ARO:3002868|dfrG	36.2	130	160	165	1.13e-28	102
k119_54216_3	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	35.7	157	160	166	4.62e-28	101
k119_54216_3	SARG|gb|CBL80435.1|ARO:3002869|dfrK	31.6	158	160	163	1.20e-27	100
k119_54216_3	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	31.6	158	160	163	1.20e-27	100
k119_54216_3	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	35.4	130	160	163	2.40e-27	99.4
k119_153074_6	SARG|gb|MBY8651252.1|ARO:3007190|vanX_in_vanP_cl	65.9	41	50	202	1.10e-17	70.9
k119_153074_6	SARG|gi|654471747|ref|WP_027941974.1|	58.5	41	50	202	2.66e-14	62.0
k119_153074_6	SARG|gi|522064112|ref|WP_020575321.1|	67.6	37	50	206	2.81e-14	62.0
k119_153074_6	SARG|gi|748291568|ref|WP_039833226.1|	55.0	40	50	202	7.31e-14	60.8
k119_153074_6	NCBI|WP_063856768.1|1|1|vanX-Ac1|vanX-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase_VanX-Ac1|AMR|glycopeptide	55.8	43	50	204	1.05e-13	60.5
k119_153074_6	SARG|CAB61231	46.7	45	50	202	1.43e-13	60.1
k119_153074_6	ResF|VanHAX_NC_1_NoAcc_3	46.7	45	50	205	1.49e-13	60.1
k119_153074_6	SARG|gi|740152778|ref|WP_037997107.1|	50.0	44	50	209	1.56e-13	60.1
k119_153074_6	SARG|gi|521086979|ref|WP_020417884.1|	51.2	43	50	202	2.81e-13	59.3
k119_153074_6	SARG|AAY52006	48.9	45	50	202	3.93e-13	58.9
k119_54366_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	35.7	241	245	258	1.58e-44	149
k119_54366_2	SARG|gi|1035670474|ref|WP_064517458.1|	37.1	251	245	648	8.38e-43	152
k119_54366_2	SARG|gi|1035717981|ref|WP_064557480.1|	37.1	251	245	648	8.38e-43	152
k119_54366_2	SARG|gi|736472622|ref|WP_034494292.1|	36.6	243	245	648	5.08e-40	144
k119_47589_2	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	36.4	88	89	447	3.10e-14	65.1
k119_9290_3	SARG|gb|AML99881.1|ARO:3001327|mdtK	29.3	191	195	474	1.43e-18	81.6
k119_76734_1	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	37.1	116	262	341	1.31e-13	68.6
k119_76734_1	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	36.5	115	262	364	8.91e-13	66.2
k119_76734_1	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	36.5	115	262	364	8.91e-13	66.2
k119_76734_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.7	122	262	231	1.01e-11	62.0
k119_76734_1	CARD|gb|AEX49906.1|ARO:3003583|basS	34.5	113	262	477	1.63e-11	62.8
k119_76734_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	29.5	122	262	232	1.91e-11	61.2
k119_76734_1	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	31.4	102	262	359	2.17e-08	53.1
k119_47913_3	megares|MEG_7432|Drugs|Glycopeptide|VanD-type_resistance_protein|VANHD_3	45.1	71	80	192	2.41e-16	68.6
k119_47913_3	SARG|gi|511041763|ref|WP_016295755.1|	45.1	71	80	202	2.84e-16	68.6
k119_47913_3	SARG|AY082011.1.gene8.p01	45.1	71	80	202	2.84e-16	68.6
k119_153489_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	30.4	135	359	229	3.17e-13	67.4
k119_153489_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	32.0	122	359	239	9.08e-13	66.2
k119_153489_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	28.8	139	359	235	1.58e-12	65.5
k119_153489_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.9	119	359	230	3.69e-12	64.3
k119_153489_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	28.6	119	359	232	2.33e-11	62.0
k119_153489_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	28.6	119	359	232	2.33e-11	62.0
k119_153489_1	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	29.2	120	359	231	3.12e-11	61.6
k119_153489_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	26.7	172	359	231	5.70e-11	60.8
k119_153489_1	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	26.7	172	359	231	7.71e-11	60.5
k119_153489_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	26.7	172	359	231	1.04e-10	60.1
k119_118225_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	35.7	230	411	451	1.28e-34	132
k119_118225_2	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.3	222	411	885	1.86e-13	71.2
k119_118225_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.3	215	223	219	4.23e-44	146
k119_118225_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.0	225	223	231	4.04e-38	131
k119_118225_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.7	223	223	232	4.15e-38	131
k119_118225_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	35.2	227	223	231	1.13e-37	130
k119_118225_3	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.8	218	223	223	3.63e-37	128
k119_118225_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.0	228	223	233	5.20e-36	125
k119_118225_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.8	227	223	232	2.81e-35	124
k119_118225_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.8	227	223	232	2.81e-35	124
k119_118225_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.4	218	223	219	2.84e-35	123
k119_118225_3	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.3	225	223	247	2.90e-35	124
k119_118320_10	SARG|gi|686448604|ref|WP_031928572.1|	28.4	394	451	451	5.66e-47	167
k119_118320_10	SARG|gi|446573700|ref|WP_000651046.1|	28.7	394	451	451	1.52e-46	166
k119_118320_10	SARG|gi|686396521|ref|WP_031908504.1|	28.6	398	451	451	2.11e-46	165
k119_118320_10	SARG|gi|446573693|ref|WP_000651039.1|	28.4	394	451	451	2.11e-46	165
k119_118320_10	SARG|gi|446573692|ref|WP_000651038.1|	28.4	394	451	451	2.11e-46	165
k119_118320_10	SARG|gi|686432388|ref|WP_031921070.1|	28.5	396	451	451	2.93e-46	165
k119_118320_10	SARG|gi|516415429|ref|WP_017804827.1|	28.6	398	451	451	2.93e-46	165
k119_118320_10	SARG|gi|446573711|ref|WP_000651057.1|	28.6	398	451	451	2.93e-46	165
k119_118320_10	SARG|gi|537465183|ref|WP_020976941.1|	28.4	394	451	451	4.08e-46	164
k119_118320_10	SARG|gi|686251508|ref|WP_031837026.1|	28.6	398	451	451	4.08e-46	164
